AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07368959

Status	RECRUITING
Phase	Phase 3
Sponsor	Aurion Biotech
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (4)

- (All ocular criteria apply to the study eye unless noted otherwise)
- Have corneal edema secondary to corneal endothelial dysfunction, requiring surgery (full- or partial-thickness endothelial keratoplasty)
- BCVA between 65 ETDRS letters (approximate 20/50 Snellen equivalent) and 5 ETDRS letters (approximate 20/800 Snellen equivalent)
- Be pseudophakic with PCIOL

Exclusion (3)

- (All ocular criteria apply to the study eye unless noted otherwise)
- Have progressive corneal dystrophies or degenerations
- Have visually significant corneal or other ocular pathologies

Locations (12 total)

Investigational Site 2, Mesa, Arizona, United States
Investigational Site 6, Little Rock, Arkansas, United States
Investigational Site 9, Fort Collins, Colorado, United States
... and 9 more locations